EarlySign Announces Strategic Collaboration Agreement with Roche on AI Solution for Early Detection of Lung Cancer

Global Agreement Calls for Development and Commercialization of EarlySign LungFlag™ to Accelerate Earlier Identification and Treatment of Lung Cancer TEL AVIV, Israel , July 7, 2022 /PRNewswire/ -- Medial EarlySign (earlysign.com), a pioneering company developing Artificial Intelligence (AI) based clinical predictive analytics, announced today the signing of a new partnership with Roche, which will focus on innovative, evidence-based solutions for early detection of lung cancer.  In 2020, over 235,000 people in the US[1] and over 2.2 million people worldwide[2] were diagnosed with lung cancer.  Lung cancer has the second largest incidence of all cancers and is the deadliest cancer for both men and women. The goal of this new collaborative effort is to deliver validated clinical machine learning models to advance lung cancer identification which can lead to earlier diagnosis and treatment.  Early identification of high-risk individuals has the potential to improve lung cancer survival rates by finding the disease at an earlier stage when it is more likely to be curable. By using proven, highly accurate models based on variety of signals including basic demographic, medical, drug, and routine clinical lab data, EarlySign's LungFlag™ is designed to help providers focus additional effort on enriched ... Full story available on Benzinga.com